Source: privateequitywire

Oxford BioTherapeutics: Calculus Capital invests GBP2 million in Oxford BioTherapeutics

Calculus Capital, an Enterprise Investment Scheme (EIS) and Venture Capital Trust (VCT) specialist, has invested GBP2 million in Oxford BioTherapeutics (OBT), a clinical-stage oncology company that is developing next-generation cancer treatments.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Est. Annual Revenue
Est. Employees
Christian Rohlff's photo - Founder & CEO of OBT

Founder & CEO

Christian Rohlff

CEO Approval Rating

86/100

OBT is a biotechnology company that focuses on the discovery and development of therapeutics for the treatment of cancer. Read more